HCV Recombinant Viruses Lacking HVR1 for Vaccine Development
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of effective cell culture systems for hepatitis C virus (HCV) research has been hindered by the lack of appropriate systems for studying the complete viral life cycle and the identification of new therapeutics and vaccines, due to the virus's genetic heterogeneity and the immunological decoy function of the Hypervariable Region 1 (HVR1).
Innovation Solution
The creation of infectious recombinant HCV strains lacking HVR1, which allows for the production of viable viruses and the identification of non-HVR1 based immune responses, enabling the development of vaccines and diagnostics, as well as the study of virus-host interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If HVR1 is included in HCV strains, then the virus exhibits natural genetic heterogeneity and immune evasion capability, but it acts as an immunological decoy that hinders the development of effective vaccines and therapeutics
Solution Approach 1:
The patent extracts and removes the HVR1 region from the HCV genome to create recombinant virus strains. This deletion eliminates the immunological decoy function of HVR1 while preserving the essential viral components needed for vaccine development, thereby resolving the contradiction between immune evasion capability and vaccine manufacturability
2Reliability
If HVR1 is present in HCV strains, then the virus maintains its natural infectivity and variability, but it prevents accurate identification of non-HVR1 based immune responses
Solution Approach 1:
By removing HVR1 from the viral genome, the patent eliminates the confounding variable that interferes with immune response measurement. This allows for precise identification of immune responses targeted against conserved viral regions, while the virus maintains sufficient infectivity for reliable experimental studies
3Adaptability or versatility
If HCV genetic heterogeneity is maintained across all regions, then the virus represents authentic clinical isolates, but it complicates the development of genotype-specific therapeutics and vaccines
Solution Approach 1:
The patent segments the HCV genome by separating the variable HVR1 region from the conserved viral components. This segmentation allows researchers to study and develop therapeutics and vaccines targeting the stable, conserved regions of the virus, thereby reducing the complexity of therapeutic development while maintaining an understanding of viral heterogeneity
Solution Approach 2:
By extracting and removing the highly variable HVR1 region, the patent creates a standardized viral platform that reduces genetic complexity. This enables the development of genotype-specific therapeutics and vaccines that can be more easily adapted across different HCV strains without being confounded by HVR1 variability
Data Source
AI summary
The present inventors used the previously developed H77/JFH 1T27OOC,A4O8OT (1a/2a), J4/JFH 1T2996C,A4827T,ΔHVRI (1b/2a), J6/JFH 1ΔHVRI (2a/2a), J8/JFH 1ΔHVRI (2b/2a), S52/JFH 1T27i8G,τ7i6oc (3a/2a), SA13/JFH 1C34O5G,A3696G (5a/2a) and HK6a/JFH 1T1389c,A1590G (6a/2a) constructs for the deletion of Hypervariable Region 1 (HVR1) to construct viable, JFH 1 (genotype 2a) based, genomes. The present inventors serially passaged the viruses in cell culture obtaining relatively high HCV RNA titers and infectivity titers. Sequence analysis of the viruses identified mutations adapting H77/JFH 1T27OOC,A4O8OT,ΔHVR1 (1a/2a), J8/JFH 1ΔHVR1 (2b/2a), S52/JFH 1T2718G,T716OC,ΔHVR1 (3a/2a) and J4/JFH 1T2996C,A4827T,ΔHVR1 (1b/2a) to the HVR1 deletion.